INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.18 USD | -1.67% |
|
-14.49% | -27.61% |
| May. 08 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Transcript : InflaRx N.V. - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 600K 646K | Sales 2025 * | 1.71M 1.85M | Capitalization | 64.51M 69.48M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -49.54M | Net income 2025 * | -61M -65.69M | EV / Sales 2024 * | 21.6 x |
| Net cash position 2024 * | 51.55M 55.52M | Net cash position 2025 * | 7.3M 7.86M | EV / Sales 2025 * | 33.4 x |
| P/E ratio 2024 * |
-1.48
x | P/E ratio 2025 * |
-1.28
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 day | -1.67% | ||
| 1 week | -14.49% | ||
| Current month | -13.87% | ||
| 1 month | -22.37% | ||
| 3 months | -22.37% | ||
| 6 months | -7.81% | ||
| Current year | -27.61% |
1 week
1.17
1.41
1 month
1.171.55
Current year
1.172.10
1 year
1.145.20
3 years
0.787.25
5 years
0.7843.34
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.18 | -1.67% | 226,429 |
| 24-05-09 | 1.2 | 0.00% | 306,652 |
| 24-05-08 | 1.2 | -3.23% | 264,912 |
| 24-05-07 | 1.24 | -4.25% | 187,160 |
| 24-05-06 | 1.295 | -6.16% | 236,410 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.096
EUR
Average target price
8.375
EUR
Spread / Average Target
+664.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.61% | 69.48M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- IFRX Stock
